
The pharmaceutical industry is currently navigating an era of unprecedented volatility where the success of a blockbuster drug often depends less on the molecule itself and more on the precision of the commercial execution. As patents for established therapies expire and generic competition intensifies, manufacturers find themselves in a race to maintain relevance with a medical community that is increasingly










